Kymera begins phase 1 trial of KT-485, receives $20M from Sanofi

June 9, 2026 7:00 AM

Kymera Therapeutics Inc. (NASDAQ: KYMR) announced that the first participant has been dosed in a phase 1 clinical trial of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found